Tylenol maker Kenvue blasts Trump administration's autism claim

Kenvue shares fell over 6% midday Monday and are down 20% in the last month following reports that President Trump and Health Secretary Robert F. Kennedy Jr. are expected to publicly link Tylenol use during pregnancy to autism, reviving a medical controversy. Tylenol's active ingredient, acetaminophen, is critical to Kenvue's self-care segment, which accounts for 42% of its total revenue, prompting the company to issue a strong denial, asserting no credible evidence supports such a connection. Analysts view this development as particularly damaging, potentially disrupting Tylenol's market share gains and casting a shadow over Kenvue's turnaround trajectory.

Analysis

Kenvue Inc. (KVUE) is facing significant headline and financial risk following reports that the Trump administration intends to publicly link its flagship Tylenol product to autism. The market reaction has been severe, with shares declining over 6% in midday trading and accumulating a 20% loss over the past month. This sell-off reflects the critical importance of Tylenol to Kenvue's financial health, as the product anchors the 'self-care' segment营收hich generates approximately 42% of the company's total revenue. In response, Kenvue has issued a robust denial, stating there is "no credible evidence" for such a link and emphasizing that "rigorous research" supports the safety of acetaminophen for pregnant women. The situation is particularly damaging as it threatens to derail the company's recent progress; an analyst from CFRA noted this development could reverse Tylenol's market share gains and disrupt KVUE's overall turnaround trajectory since its 2023 spin-off from Johnson & Johnson. The core uncertainty for investors is whether these high-profile allegations will materially impact consumer behavior and sales, creating a significant shadow over Kenvue's near-term outlook.

Key Decisions for Investors

• Investors should closely monitor near-term sales data and consumer sentiment for Tylenol, as any sustained drop in demand would directly impact the segment responsible for 42% of Kenvue's revenue.
• Given the stock's 20% decline in the last month, a significant portion of this headline risk may already be priced in, but the high-profile political nature of the issue creates vulnerability to further volatility and downside.
• The primary risk to the investment thesis is the potential for permanent brand impairment; therefore, it is critical to watch for formal statements from global health regulators, which could either validate Kenvue's defense or lend credibility to the allegations.